Comparative Pharmacology
Head-to-head clinical analysis: DEXASPORIN versus KENALOG.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEXASPORIN versus KENALOG.
DEXASPORIN vs KENALOG
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dexasporin is a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive properties. It binds to the glucocorticoid receptor, leading to modulation of gene expression and inhibition of pro-inflammatory mediators such as prostaglandins and leukotrienes.
Triamcinolone acetonide is a synthetic corticosteroid with potent glucocorticoid and weak mineralocorticoid activity. It binds to the glucocorticoid receptor, leading to inhibition of phospholipase A2, decreased release of arachidonic acid, and reduced synthesis of prostaglandins and leukotrienes. It also suppresses cytokine production and immune cell migration.
1 to 2 mg/kg intramuscular or intravenous every 8 hours.
Kenalog (triamcinolone acetonide) 40-80 mg intramuscularly (deep gluteal) every 4 weeks; or 0.5-1 mg/kg intravenously every 24 hours (for acute conditions).
None Documented
None Documented
3-4 hours (prolonged to 10-15 hours in renal impairment; monitor CrCl <30 mL/min)
Terminal half-life ~2-5 hours (triamcinolone acetonide); clinical duration prolonged due to crystalline depot formulation
Renal excretion (80-90% unchanged), biliary/fecal (10-20%)
Renal (primarily as metabolites), ~30% unchanged; biliary/fecal minor (≤10%)
Category C
Category C
Corticosteroid/Antibiotic Combination
Corticosteroid